<DOC>
	<DOCNO>NCT01791725</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , placebo-controlled , parallel-group , three-arm , multicenter study safety PK ELND005 administer orally 4 week . This study enroll Down Syndrome patient 18 45 year age ( inclusive ) without dementia .</brief_summary>
	<brief_title>A 4-Week Safety Study Oral ELND005 Young Adults With Down Syndrome Without Dementia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>18 45 year age Has IQ &gt; 40 ( KBIT ) Able willing brain MRI Symptoms dementia worsen cognition past year . Has history hepatitis B , hepatitis C , HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>